Advice
following a full submission:
aripiprazole oral (Abilify®) is accepted for restricted use within NHS Scotland.
Indication under review: treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
SMC restriction: restricted to initiation and management under the supervision of a child/adolescent psychiatrist.
Aripiprazole demonstrated superior efficacy to placebo in reducing manic symptoms at 4 weeks. Aripiprazole has not been directly compared to other atypical antipsychotics, none of which are licensed for this indication although they are used off-label in clinical practice.
Download detailed advice155KB (PDF)
Medicine details
- Medicine name:
- aripiprazole (Abilify)
- SMC ID:
- 891/13
- Indication:
- Treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 September 2013